<DOC>
	<DOCNO>NCT02198300</DOCNO>
	<brief_summary>Coronary bifurcation lesion pose therapeutic problem percutaneous coronary intervention ( PCI ) associate high rate periprocedural complication well high rate in-stent restenosis stent thrombosis . Provisional T-stenting ( PTS ) best treatment strategy moment . However , optimal approach coronary bifurcation treatment still subject debate , especially side branch large , easily accessible narrow long lesion . One propose alternative dedicate bifurcation stent ( DBS ) . However , large scarcity randomize trial DBS . POLBOS II study continuation POLBOS I ( POLish Bifurcation Optimal Stenting ) study , paclitaxel-eluting stent BiOSS Expert® ( Balton , Poland ) assess . Now performance sirolimus-eluting stent BiOSS LIM® ( Balton , Poland ) verify .</brief_summary>
	<brief_title>DES Versus BiOSS LIM - POLBOS II Study</brief_title>
	<detailed_description>After sign informed consent patient randomly assign one two treatment strategy : BiOSS LIM® stent implantation rDES implantation ( envelope randomization , 1:1 ) . If patient enrol rDES Group second randomization : without final kissing ballooning ( FKB ) . Clinical follow-up perform office visit telephone contact 1 12 month intervention . Adverse event monitor throughout study period . Follow-up coronary angiography perform 12 month unless clinically indicate earlier .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>stable coronary artery disease ( CAD ) nonSTsegment elevation acute coronary syndrome ( NSTEACS ) age ≥ 18 year old , de novo coronary bifurcation lesion ( include unprotected LMS ) , MV diameter ≥ 2.5 mm SB diameter ≥ 2.0 mm assess visual estimation . STelevation myocardial infarction ( STEMI ) , bifurcation Medina type 0,0,1 , serum creatinine level ≥ 2.0 mg/dl , inability take dual antiplatelet therapy 12 month , leave ejection fraction ≤ 30 % lack informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>dedicate bifurcation stent</keyword>
	<keyword>sirolimus elute stent</keyword>
</DOC>